Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01608178 · ClinicalTrials.gov registry record
Taurine Therapy for SSADH Deficiency
A clinical trial, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 7
- Enrollment target
NCT01608178: Completed study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT01608178 is a clinical trial that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01608178 has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
Background: \- Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare genetic disease that results in changes to certain brain chemicals. These chemicals may affect brain excitability, or how likely nerve cells are to turn on. Changes in brain excitability may help to explain the symptoms of the disease, including learning and memory problems, seizures, and poor balance. A supplement called taurine may help people with SSADH deficiency by working on the brain chemical GABA. GABA helps to regulate brain activity. Researchers want to see if taurine can help people with SSADH deficiency. Objectives: \- To learn more about how taurine affects the brain in people with SSADH deficiency. Eligibility: \- Individuals at least 12 years of age who have SSADH deficiency. Design: * Participants will be screened with a physical exam and medical history. They will provide blood and urine samples. They will also take taurine supplements as part of this protocol. * Participants will have two sets of study tests. One set will be given while participants are taking taurine. The second will be given when they are not taking it. Each testing session will take about 2 days to complete. * Half of the participants will have the "off taurine" testing before starting on the taurine supplement. The other half will start taking taurine first, have the "on taurine" testing, and have the "off taurine" testing about 3 months after stopping taurine. Participants may decide the order in which they will have the testing done. * Participants will have the following tests at the two test visits: * Paper and pencil tests of learning and memory. * Transcranial magnetic stimulation to study the excitability of nerve cells. * Imaging studies to show GABA receptors in the brain and measure their activity. * Electroencephalogram to measure brain waves. * Lumbar puncture to collect spinal fluid. * Participants will be monitored with regular study visits while they receive the taurine supplem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-04-27 |
| Est. Completion | 2013-12-16 |
What the finished NCT01608178 record still lists
NCT01608178 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01608178 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01608178 about?
NCT01608178 is a clinical study titled "Taurine Therapy for SSADH Deficiency". Background: \- Succinic semialdehyde dehydrogenase (SSADH) deficiency is a rare genetic disease that results in changes to certain brain chemicals. These chemicals may affect brain excitability, or how likely nerve cells are to turn on. Changes in brain excitability may help to explain the symptoms...
What is the current status of trial NCT01608178?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2012-04-27. Estimated completion is 2013-12-16.
Who is sponsoring clinical trial NCT01608178?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI